Cornea

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

Challenging choices force ophthalmologists to weigh long-term outcomes

Inhibiting ferroptosis could be crucial to reducing inflammation

At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology

Astigmatic values differed between K and TK readings

Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium"

At this year's ARVO meeting, Neda Gioia, OD, discussed the increasing patient burden of dry eye disease

Eric Donnenfeld, MD, discusses the clinical evaluation of Blink Triple Care artificial tears ahead of the 2024 ARVO meeting

John Sheppard, MD, MSc, FACs, discusses the unique biochemical traits of perfluorohexyloctane for eye dry disease and meibomian gland dysfunction

Dr Richard Lindstrom speaks about the future of dry eye and shares pearls for young eye surgeons

Dr Neda Nikpoor discusses Light Adjustable Lenses and the implications for clinicians at ASCRS 2024

At ASCRS 2024, Aurion Biotech's Global VP Eris Jordan previews upcoming clinical data from North America and Asia

Ahead of the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Laser blended vision is a proven modality for presbyopia treatment, but its principles can be reproduced with EDOF IOLs

Clara Chan, MD, shares surgical pearls for neurotrophic keratopathy and explores new pathways through neurotisation

Penetrating keratoplasty remains a popular choice for certain patients

The company, headquarted in New York and London, named OK-101 as the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat NCP

Postoperative outcomes of the tissues obtained from these donors were satisfactory

Why “acceleration” is the industry keyword for 2024

Restoration and regeneration represent a new paradigm

The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.